In Vivo

Medtechs Weigh Up Preferred Growth Strategies As Pandemic Tails Out

Spin, divest, M&A? Medtechs Will Be Delving Deep Into Their Strategy Toolbox In 2023

21 Feb 2023

Medtech M&A was at a decade low in 2022 and IPOs was a closed market, says EY life sciences partner John Babitt, who gave his thoughts on likely strategic activity in the year ahead to In Vivo.

Spin outs and restructuring plans have been plentiful at the top end of the medtech industry in the past year. The focus on portfolio pruning for long-term growth has become very visible as the industry exits more confidently from the COVID-19 pandemic.

As 2022 ended, so 2023 continued on the theme of spin outs. GE HealthCare Technologies, Inc.’s pre-announced spin was...